Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer
Enrolling By Invitation
18-99 years
All
Phase
2
1 Location
Brief description of study
The purpose of this study is to determine if a combination of two drugs, Ipatasertib and Atezolizumab, works as a treatment for residual cancer in breast or lymph nodes and have circulating tumor DNA in blood. Eligible subjects will be those with triple negative breast cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Breast Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 844085
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
